

## Video Article

# Glucose Uptake Measurement and Response to Insulin Stimulation in *In Vitro* Cultured Human Primary Myotubes

Stephanie Chanon<sup>1</sup>, Christine Durand<sup>1</sup>, Aurelie Vieille-Marchiset<sup>1</sup>, Maud Robert<sup>2</sup>, Charna Dibner<sup>3</sup>, Chantal Simon<sup>1</sup>, Etienne Lefai<sup>1</sup>

<sup>1</sup>CarMeN Laboratory, INSERM U1060, INRA 1397, University of Lyon

<sup>2</sup>Department of digestive and bariatric surgery, Obesity Integrated Center, University Hospital of Edouard Herriot, Hospices Civils de Lyon, Lyon 1 University

<sup>3</sup>Division of Endocrinology, Diabetes, Hypertension and Nutrition, Department of Clinical Medicine, Faculty of Medicine, University of Geneva

Correspondence to: Etienne Lefai at [etienne.lefai@univ-lyon1.fr](mailto:etienne.lefai@univ-lyon1.fr)

URL: <https://www.jove.com/video/55743>

DOI: [doi:10.3791/55743](https://doi.org/10.3791/55743)

Keywords: Cellular Biology, Issue 124, Skeletal muscle, glucose metabolism, insulin signaling, human myotube, insulin sensitivity, radioactivity

Date Published: 6/25/2017

Citation: Chanon, S., Durand, C., Vieille-Marchiset, A., Robert, M., Dibner, C., Simon, C., Lefai, E. Glucose Uptake Measurement and Response to Insulin Stimulation in *In Vitro* Cultured Human Primary Myotubes. *J. Vis. Exp.* (124), e55743, doi:10.3791/55743 (2017).

## Abstract

Skeletal muscle is the largest glucose deposit in mammals and largely contributes to glucose homeostasis. Assessment of insulin sensitivity of muscle cells is of major relevance for all studies dedicated to exploring muscle glucose metabolism and characterizing metabolic alterations. In muscle cells, glucose transporter type 4 (GLUT4) proteins translocate to the plasma membrane in response to insulin, thus allowing massive entry of glucose into the cell. The ability of muscle cells to respond to insulin by increasing the rate of glucose uptake is one of the standard readouts to quantify muscle cell sensitivity to insulin. Human primary myotubes are a suitable *in vitro* model, as the cells maintain many features of the donor phenotype, including insulin sensitivity. This *in vitro* model is also suitable for the test of any compounds that could impact insulin responsiveness. Measurements of the glucose uptake rate in differentiated myotubes reflect insulin sensitivity.

In this method, human primary muscle cells are cultured *in vitro* to obtain differentiated myotubes, and glucose uptake rates with and without insulin stimulation are measured. We provide a detailed protocol to quantify passive and active glucose transport rates using radiolabeled [<sup>3</sup>H] 2-deoxy-D-Glucose ([<sup>3</sup>H]2dG). Calculation methods are provided to quantify active basal and insulin-stimulated rates, as well as stimulation fold.

## Video Link

The video component of this article can be found at <https://www.jove.com/video/55743/>

## Introduction

Skeletal muscle is the largest glucose deposit in mammals and largely contributes to glucose homeostasis. This insulin responsive tissue is the primary site of the glucose uptake that is triggered by insulin stimulation<sup>1</sup>.

In type 2 diabetes, insulin resistance is observed in several tissues, including skeletal muscle, and leads to above normal blood glucose concentration. Thus, it is of major relevance to determine the level of insulin sensitivity of this tissue and its cells, whether the aim is to characterize a defect in a subject, or to evaluate the efficiency of a treatment intending to improve it. In human or animal subjects, the gold standard technique to assess insulin sensitivity is the hyperinsulinemic-euglycemic clamp. Introduced by DeFronzo in 1979<sup>2</sup> and modified since<sup>3,4</sup> then, the method allows to quantify whole body and tissues insulin responsiveness measured as the rate of glucose to be perfused under insulin stimulation to maintain normal blood glucose concentration.

Insulin sensitivity exploration can also be performed at the cell level using *in vitro* muscle models, and measurement of glucose uptake rates remains an efficient and reliable tool to quantify the biological response of the cell to insulin stimulation<sup>5,6,7</sup>. Indeed, glucose uptake measurement quantifies the cell biological response to insulin stimulation, from the binding of insulin to its receptor to translocation of GLUT4 enriched vesicles, and including intracellular signaling and phosphorylation cascades<sup>8</sup>.

This is of major interest with human samples, as differentiated myotubes maintain many features of the donor phenotype, including metabolic properties and disorders observed in the patient<sup>9,10,11,12</sup>. The myotubes displays structural, metabolic and phenotypic similarities to the skeletal muscle<sup>13,14</sup>, including the expression of glucose transporters<sup>15</sup> and the cellular insulin signaling machinery<sup>16</sup>. Thus, measurement of the glucose uptake in primary myotubes is of relevance to characterizing the muscle phenotype of a donor, or investigating the effect of an intervention (drug, nutrition, or physical activity) on the insulin sensitivity in the muscle cell.

The measurement of glucose uptake on cultured myotubes also is a reliable tool when performing experiments that modify insulin sensitivity<sup>17,18</sup>. The *in vitro* model is suitable for the test of any compounds that could improve insulin responsiveness, or could prevent or reverse acquired or induced insulin resistance<sup>19,20,21,22,23</sup>.

Here we describe a detailed protocol to culture and differentiate human myotubes and to measure cell glucose uptake rates. The method is applicable to any source of human muscle precursor cells, whether they come from in-lab preparations, collaboration, or commercially available suppliers. Immortalized muscle cell lines, like C2C12 and L6, respectively from mouse and rat origin, can also be used for glucose uptake measurement with this protocol<sup>1</sup>.

We provide a detailed protocol to quantify rates in basal and insulin-stimulated states using radiolabeled [<sup>3</sup>H]2dG. The use of a labeled glucose analog allows accurate determination of glucose entry with reduced starting material, a common condition when working with primary cells. The modified glucose molecule is unable to enter metabolic pathways, and thus, accumulates within the cell, allowing reliable quantification via total cell radioactivity. Experimental conditions include the use of a glucose transport inhibitor (cytochalasin B), and measurements are performed with and without insulin. This combination allows the determination of glucose active entry rates, as well as the calculation of fold change for the insulin response index. The method is presented with one dose of insulin during a single incubation time, but the protocol can easily be modified for dose response or time course experiments<sup>12</sup>.

## Protocol

### 1. Preparation of Cell Culture Media and Solutions

#### 1. Preparation of culture media

1. Prepare proliferation medium (PM) by supplementing Ham's F-10 medium with glutamine (2 mM), penicillin/streptomycin (5 µg/mL final), 2% Fetal Calf Serum (FCS) and 2% serum substitute.
2. Prepare differentiation medium (DM) by supplementing Dulbecco's Modified Eagle Medium (DMEM) with glutamine (2 mM), penicillin/streptomycin (5 µg/mL final), and 2% FCS.

#### 2. Preparation of glucose uptake solutions

Caution: Handling of radioactive material is only allowed in a restricted and controlled area by authorized personnel. Material and waste must be handled according to appropriate procedures, guidelines and local legislation.

1. To prepare X-Dulbecco's phosphate-buffered saline (X-DPBS), make a solution of DPBS containing 0.2% (w/v) (final concentration) bovine serum albumin (BSA). Filter the solution through a 0.2 µm filter. Store at 4 °C.
2. To prepare cold 2-deoxy-D-glucose (2dG) solution, weigh 16.4 mg of 2dG and solubilize in 10 mL distilled water to obtain a 10 mM solution. Store at 4 °C.
3. Add 600 µL of cold 2dG and 6 µL of radiolabeled [<sup>3</sup>H] 2dG to 5400 µL of X-DPBS to obtain the radiolabeled 2dG (2dG\*) solution.

NOTE: The final concentration is 1 mM 2dG and labeling is 1 µCi/mL.

1. Set aside a 20 µL aliquot (TC20) of radiolabeled 2dG\* solution.

#### 3. Preparation of incubation mixtures

1. For the cytochalasin B mixture, add 2 µL of 20 mM cytochalasin B to 2 mL of radiolabeled 2dG\* solution.  
NOTE: Stock solution of cytochalasin B is at 10 mg/mL in dimethyl sulfoxide (DMSO).
2. For the DMSO mixture, add 4 µL of DMSO to the remaining 4 mL of radiolabeled 2dG\* solution.

### 2. Culture of Human Primary Muscle Cells

#### 1. Seeding of 6-well plates with human muscle satellite cells

NOTE: Use in-house (see reference<sup>24</sup> for details) or commercially available human muscle satellite cells from a frozen vial (containing 250,000 cells). The following procedure is given for 250,000 cells in order to obtain one 6-well plate necessary for the measurement of glucose uptake in a single condition.

1. Rapidly thaw frozen vials of in-house<sup>24</sup> or commercial preparations of human muscle satellite cells in pre-warmed water (37 °C) until only a small ice block remains in the vial.
2. Pour directly into a 50 mL plastic tube containing 10 mL of pre-warmed (37 °C) PM.
3. Centrifuge for 5 min at 500 x g and discard the supernatant.
4. Gently resuspend the cell pellet with 18 mL of pre-warmed PM (to obtain 42,000 cells per 3 mL of medium). Distribute 3 mL in each well of a 6-well plate (9.6 cm<sup>2</sup>).

NOTE: The six individual wells of a plate are required to perform a duplicate measurement of glucose uptake for the following conditions: passive transport inhibition (wells 1 and 2), basal rate (wells 3 and 4) and insulin stimulated rate (wells 5 and 6). Repeat as many six-well plates as distinct treatments are needed.

5. Incubate in standard culture conditions (37 °C, 5% CO<sub>2</sub>) until cells reach 90% confluence.

NOTE: This step takes between 48 - 72 h depending on the cell batch. Do not change medium during this step.

#### 2. Differentiation of muscle cells

1. Remove PM (after 48-72 h) and replace with pre-warmed DM (3 mL per well). Incubate at 37 °C, 5% CO<sub>2</sub>.

NOTE: Differentiation takes five days to reach a stable state where cells are aligned and polynucleated. Typically, the primary myotubes are cultured in a 1 g/L glucose medium. Therefore, to avoid glucose depletion during culture, fill the plate with 3 mL medium to ensure that enough glucose substrate is available for the cells at all time.

2. Replace DM medium every two days.

NOTE: From this point, myotubes are stable for up to 7 days without any significant change and glucose uptake measurement can be performed at any time.

#### 3. Muscle cells treatment (optional)

NOTE: Primary myotubes can be treated for several days to induce modification (drug test, inhibitors/activators of signaling pathway, etc.) before insulin stimulation and glucose uptake measurements. Muscle cells can be submitted to any treatment that may have an impact on insulin sensitivity, and glucose uptake measurement will quantify this impact. For example, incubation of muscle cells with the saturated fatty acid palmitate promotes insulin resistance, and cells display reduced insulin stimulated glucose uptake.

1. Prepare 12 mL of DM supplemented with 10% BSA (fatty acid free) and 0.5 mL palmitate (PALM). Prepare 12 mL of DM supplemented with 10% BSA (fatty acid free) only.
2. Prepare two 6-well plates with human primary myotubes, and culture them as described in sections 2.1 and 2.2 (with 5 days of differentiation).
3. On day 5, wash each well with 2 mL of PBS. To one plate, add 2 mL of DM containing PALM. To the other plate add 2 mL of BSA only containing DM.
4. Incubate for 48 h at 37 °C, 5% CO<sub>2</sub>.

### 3. Insulin Stimulation

1. Wash differentiated muscle cells twice with 2 mL PBS.
2. Remove PBS carefully and incubate with 3 mL of DM without FCS for 3 h (37 °C, 5% CO<sub>2</sub>) for serum depletion.
3. Replace media in all wells with 3 mL of DM without FCS. Add 100 nM insulin to wells 5 and 6.
4. Incubate human myotubes culture for 1 h (37 °C, 5% CO<sub>2</sub>).

### 4. Glucose Uptake

1. After 1 h of insulin stimulation, wash wells twice with X-DPBS (1 mL per wash).
2. Add 1 mL of cytochalasin B mixture to wells 1 and 2, and 1 mL of DMSO mixture to wells 3 - 6. Incubate for 15 min (37 °C, 5% CO<sub>2</sub>). At the end of the incubation, immediately place the plate on ice.

### 5. Cell Lysis

1. Wash the cells twice with 1 mL of ice cold PBS.
2. Lyse the cells in each well with 600 µL of 50 mM NaOH. Incubate on ice for 5 min and mix gently with slow orbital rotation.  
NOTE: If the lysate is too viscous, dilute with up to 1.5 mL NaOH.
3. Using a pipette, resuspend and collect the cell lysate.

### 6. Determination of Radiolabeled Glucose

1. Put 400 µL of each cell lysate in a liquid scintillation counting vial. Prepare a negative control vial with 400 µL of 50 mM NaOH, and a positive control vial with 20 µL of TC20 (from step 1.2.3.1).
2. Add 4 mL of liquid scintillation solution to each vial. Close the cap and mix each vial thoroughly (1-2 s).
3. Insert each vial in a liquid scintillation counter and measure the radioactivity according to the manufacturer's instruction. Record counts per min (CPM) for each scintillation vial for 10 min.  
NOTE: CPM = "disintegrations per minute" x "counting efficiency".

### 7. Rate of Glucose Uptake

1. Use the remaining lysate (200 µL; from step 5.2) to measure the protein concentration. Determine the protein concentration of each cell lysate using Bradford<sup>25</sup> or an equivalent method. Calculate total protein quantity (Q) in mg for each well.
2. To obtain TC1 (the value for 1 µL of radiolabeled 2dG\*), divide the CPM value of TC20 by 20.
3. For each vial, calculate the rate of glucose uptake as follows:

$$R = \left[ \left( \frac{CPM}{TC1} \right) * \left( \frac{600}{400} \right) * \left( \frac{1}{Q} \right) \right] / 15$$

NOTE: R is measured in pmol/mg/min. Mean of R for wells 1 - 2 gives passive transport rate, R<sub>p</sub>. Mean of R for wells 3-4 gives basal total transport rate, R<sub>bt</sub>. Mean of R for wells 5-6 gives insulin stimulated total transport rate, R<sub>it</sub>.

1. Calculate the basal active transport rate (R<sub>ba</sub>) as follows:

$$R_{ba} = R_{bt} - R_p$$

2. Calculate the insulin stimulated active transport rate (R<sub>ia</sub>) as follows:


$$R_{ia} = R_{it} - R_p$$

NOTE: In insulin responsive cells like myotubes, glucose uptake rates are usually represented by three values: R<sub>ba</sub>, R<sub>ia</sub>, and the fold insulin stimulation as R<sub>ia</sub>/R<sub>ba</sub>.


## Representative Results

On day 3, myoblasts reach confluence (**Figure 1A**). The myoblasts at this stage are typically mononucleated. Medium was changed and on day 8, differentiation was completed (**Figure 1B**) (protocol section 2). After 5 days of differentiation, myotubes are aligned and typically polynucleated. Human primary myotubes were subjected to a palmitate or a BSA-only treatment before glucose uptake rate measurement. Cells were incubated for 48 h with palmitate 0.5 mM in BSA (PALM) or BSA alone (BSA). Insulin stimulation was performed (protocol section 3) and glucose uptake was measured (protocol section 4). **Figure 2** shows glucose uptake rate in a control condition (BSA) and a treatment condition (PALM). Nonspecific uptake is quantified in myotubes incubated with cytochalasin B. Basal and insulin stimulated glucose uptake rates can be compared in BSA and PALM conditions. Insulin significantly increases glucose transport in the BSA condition ( $p < 0.01$ ). The insulin stimulated glucose uptake rate is significantly lower in myotubes treated with PALM ( $p < 0.05$ ). Furthermore, the human myotube cell response to insulin can also be expressed as fold change. **Figure 3** demonstrates that the response to insulin is decreased in myotubes treated with PALM when compared to control ( $p < 0.05$ ).


Despite limited expression of GLUT4 protein in cultured myotubes, primary muscle cells are able to respond to insulin with an increase in glucose uptake (**Figure 2**). The mean fold change observed is  $\sim 1.3$ , similar to what was described by other groups with human muscle cells<sup>6,7,10,26,27</sup>. Induction of insulin resistance in muscle cells with saturated fatty acid is commonly described in mouse, rat and human muscle cells, and has been demonstrated to reduce glucose uptake of treated muscle cells<sup>28,29,30,31,32,33,34</sup>. We performed palmitate (0.5 mM) incubation for 48 h and observed a decrease in the rate of basal and insulin stimulated glucose uptake and a decrease in the insulin fold change, reflecting the insulin resistant state. The incubation time used in this manuscript has been chosen to fully demonstrate the inhibitory effect on glucose uptake. Shorter incubation times can also produce insulin resistance and reduced glucose uptake<sup>31,32,33,34</sup>. Lower and thus more physiological concentrations can be used *in vitro*, as well as dose response and/or time course experiments, and comparison with the effect of unsaturated fatty acids like oleate<sup>29,35</sup>.



**Figure 1: *In Vitro* Primary Human Myotubes.** Images of human myotubes at 2 stages of culture obtained using an optical microscope are shown. (A) Day 3 of myoblast culture at confluence. (B) At day 8 (5 days of differentiation), myotubes are aligned. Scale bar = 200  $\mu\text{m}$ . [Please click here to view a larger version of this figure.](#)



**Figure 2: Effect of Insulin Stimulation on Glucose Uptake Rate in Human Myotubes Under BSA and PALM Conditions.** Myotubes were treated with BSA alone or 0.5 mM PALM for 48 h. After medium change and 3 h serum depletion, specific glucose uptake rate (in pmol/mg/min) was measured in the absence (-) or in the presence (+) of insulin (1 h, 100 nM). Data are mean  $\pm$  sem of four independent experiments using myotubes from four different donors. <sup>#</sup> $P < 0.05$  compared with the basal value; <sup>\*</sup> $P < 0.05$  compared with BSA insulin stimulation value. [Please click here to view a larger version of this figure.](#)



**Figure 3: Fold Insulin Response in BSA and PALM Culture Conditions.** Ratio of insulin stimulated on basal glucose transport rate in BSA and PALM conditions. This ratio gives the fold glucose uptake rate upon insulin stimulation (100 nM). \*P <0.05 compared to BSA condition (n = 4). [Please click here to view a larger version of this figure.](#)

## Discussion

Glucose uptake is a key biological measurement for testing activators or inhibitors on cell culture and how they impact glucose use, and the ability of the cell to respond to insulin. The method described here has been shown to be quick and reliable and has been widely used in many studies using primary myotubes from healthy subjects and/or metabolically affected patients<sup>6,7,10,12,21,26,27,36,37</sup>. With only one 6-well plate, rates can be obtained in duplicates for total basal transport, basal active transport, and insulin-stimulated active transport. These three values fully describe the insulin sensitivity of the *in vitro* cultured muscle cells.

Primary muscle cells are routinely cultured on collagen-coated plates. When using cell lines like C2C12 or L6, non-coated plates can be used. To maximize insulin response, it is important to deplete insulin from the muscle cells before stimulation in order to have the lowest possible basal state. The 3 h incubation time indicated in this protocol can be modified as per cell stability upon insulin and/or serum starvation. The 3 h incubation with insulin is followed by a 15-min incubation with radiolabeled glucose. The purpose of the one-hour incubation with insulin is to allow translocation of any available GLUT4 containing vesicles to the membrane in order to achieve maximal glucose uptake rate. Previous tests showed that shorter incubation times (15 and 30 min) did not achieve maximal rates. Persistence of insulin stimulation during the 15 min with radiolabeled 2dG is not mandatory as it did not affect the measurement (personal data). Moreover, the same radiolabeled 2dG mixture can be added to all tested wells. For cell lysis, the volume of NaOH can be modified according to the cell characteristics. When working with cells that contain high levels of fatty acids *i.e.* for very viscous lysates, the volume of NaOH can be increased up to 1.5 mL.

The method uses radiolabeled material that enhances the sensitivity of the measurement, but requires that the protocol be performed in controlled areas. Materials and wastes need to be handled according to the local safety guidelines. For non-equipped laboratories, other colorimetric and fluorescence quantification<sup>38</sup> methods are available. In non-radioactive assays, fluorescence intensity can be measured after incubation of the cells with a fluorescent D-glucose analog 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG). With this analog, some groups report that insulin lost its physiological effects in L6 cells<sup>39</sup>, whereas other groups showed that insulin still increases glucose uptake (in human primary muscle cells)<sup>38</sup>. Due to low GLUT4 expression, quantification of insulin stimulated glucose uptake in cultured muscle cells is reduced compared to *in vivo* conditions<sup>6,16</sup>. It is thus important to further characterize insulin responsiveness of the cultured muscle cells through other approaches. Measurements of phosphorylation status of key proteins of the insulin-signaling pathway (like Akt/PKB and/or GSK3) using immuno-detection can be used<sup>14,21,31</sup>. At the enzymatic level, glycogen synthesis, glucose and/or lipid oxidation can also be assessed in conditions with and without insulin<sup>14,26,31</sup>. Any other cell type (whether it responds to insulin or not) could theoretically be analyzed as all cells can actively or passively uptake glucose. The insulin-stimulated wells can thus be replaced by any other appropriate treatment.

The use of human primary myotube implies that muscle cells have reached a differentiation state consistent with enough expression of GLUT4 protein. If the preparation contains non-muscle cells or essentially myoblasts, glucose uptake values in insulin stimulation condition will not be different from the basal state ( $R_{ia}$  versus  $R_{ba}$ ), mainly due to the predominance of GLUT1 transporter.

Insulin can be added to the primary muscle cell culture medium to promote and enhance muscle cell proliferation and differentiation. Nevertheless, insulin has also been demonstrated to induce insulin resistance in chronic stimulation<sup>40,41,42</sup>. In our experiments, human primary muscle cells properly differentiate only upon medium change with reduced serum. We thus prefer not to add external insulin during culture to preserve the cells from chronic stimulation before assessment of insulin responsiveness. Finally, the method requires several washing steps. Therefore, care must be taken to not detach cells from the plate as it can happen with primary cells.



## Disclosures

The authors have nothing to disclose.

## Acknowledgements

The authors acknowledge Anne Charrié at the Radiobiology service (Lyon-Sud hospital) and the Fond National Suisse (FNS) for their financial support.

## References

1. Stump, C. S., Henriksen, E. J., Wei, Y., & Sowers, J. R. The metabolic syndrome: role of skeletal muscle metabolism. *Ann Med.* **38** (6), 389-402 (2006).
2. DeFronzo, R. A., Tobin, J. D., & Andres, R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol.* **237** (3), E214-223, (1979).
3. Fossum, E., Høiegggen, A., Moan, A., Nordby, G., & Kjeldsen, S. E. Insulin sensitivity relates to other cardiovascular risk factors in young men: validation of some modifications of the hyperinsulinaemic, isoglycaemic glucose clamp technique. *Blood Press Suppl.* **2** 113-119, (1997).
4. Heise, T. *et al.* Euglycaemic glucose clamp: what it can and cannot do, and how to do it. *Diabetes Obes Metab.* **18** (10), 962-972 (2016).
5. Sell, H., Jensen, J., & Eckel, J. Measurement of insulin sensitivity in skeletal muscle in vitro. *Methods Mol Biol.* **933** 255-263 (2012).
6. Sarabia, V., Lam, L., Burdett, E., Leiter, L. A., & Klip, A. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. *J Clin Invest.* **90** (4), 1386-1395 (1992).
7. Sarabia, V., Ramlal, T., & Klip, A. Glucose uptake in human and animal muscle cells in culture. *Biochem Cell Biol.* **68** (2), 536-542, (1990).
8. Richter, E. A., & Hargreaves, M. Exercise, GLUT4, and skeletal muscle glucose uptake. *Physiol Rev.* **93** (3), 993-1017 (2013).
9. Gaster, M., Kristensen, S. R., Beck-Nielsen, H., & Schroder, H. D. A cellular model system of differentiated human myotubes. *Apmis.* **109** (11), 735-744, (2001).
10. Bouzakri, K. *et al.* Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. *Diabetes.* **52** (6), 1319-1325, (2003).
11. Scheele, C. *et al.* Satellite cells derived from obese humans with type 2 diabetes and differentiated into myocytes in vitro exhibit abnormal response to IL-6. *PLoS One.* **7** (6), e39657 (2012).
12. Jackson, S. *et al.* Decreased insulin responsiveness of glucose uptake in cultured human skeletal muscle cells from insulin-resistant nondiabetic relatives of type 2 diabetic families. *Diabetes.* **49** (7), 1169-1177, (2000).
13. Aas, V. *et al.* Are cultured human myotubes far from home? *Cell Tissue Res.* **354** (3), 671-682 (2013).
14. Bakke, S. S. *et al.* Myotubes from severely obese type 2 diabetic subjects accumulate less lipids and show higher lipolytic rate than myotubes from severely obese non-diabetic subjects. *PLoS One.* **10** (3), e0119556 (2015).
15. Stuart, C. A. *et al.* Hexose transporter mRNAs for GLUT4, GLUT5, and GLUT12 predominate in human muscle. *Am J Physiol Endocrinol Metab.* **291** (5), E1067-1073 (2006).
16. Al-Khalili, L. *et al.* Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content. *Cell Mol Life Sci.* **60** (5), 991-998 (2003).
17. Tsuka, S. *et al.* Promotion of insulin-induced glucose uptake in C2C12 myotubes by osteocalcin. *Biochem Biophys Res Commun.* **459** (3), 437-442 (2015).
18. Gorbunov, E. A., Nicoll, J., Myslivets, A. A., Kachaeva, E. V., & Tarasov, S. A. Subetta Enhances Sensitivity of Human Muscle Cells to Insulin. *Bull Exp Biol Med.* **159** (4), 463-465 (2015).
19. Breen, D. M., Sanli, T., Giacca, A., & Tsiani, E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. *Biochem Biophys Res Commun.* **374** (1), 117-122 (2008).
20. Pinnamaneni, S. K., Southgate, R. J., Febbraio, M. A., & Watt, M. J. Stearoyl CoA desaturase 1 is elevated in obesity but protects against fatty acid-induced skeletal muscle insulin resistance in vitro. *Diabetologia.* **49** (12), 3027-3037 (2006).
21. Gastebois, C. *et al.* Transition from physical activity to inactivity increases skeletal muscle miR-148b content and triggers insulin resistance. *Physiol Rep.* **4** (17) (2016).
22. Naimi, M., Tsakiridis, T., Stamatatos, T. C., Alexandropoulos, D. I., & Tsiani, E. Increased skeletal muscle glucose uptake by rosemary extract through AMPK activation. *Appl Physiol Nutr Metab.* **40** (4), 407-413 (2015).
23. Feng, Y. Z. *et al.* PPARdelta activation in human myotubes increases mitochondrial fatty acid oxidative capacity and reduces glucose utilization by a switch in substrate preference. *Arch Physiol Biochem.* **120** (1), 12-21 (2014).
24. Perrin, L. *et al.* Human skeletal myotubes display a cell-autonomous circadian clock implicated in basal myokine secretion. *Mol Metab.* **4** (11), 834-845 (2015).
25. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* **72** 248-254, (1976).
26. Bouzakri, K. *et al.* Malonyl CoenzymeA decarboxylase regulates lipid and glucose metabolism in human skeletal muscle. *Diabetes.* **57** (6), 1508-1516 (2008).
27. Shemyakin, A. *et al.* Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. *Diabetes.* **60** (8), 2061-2067 (2011).
28. Alkhateeb, H., Chabowski, A., Glatz, J. F., Luiken, J. F., & Bonen, A. Two phases of palmitate-induced insulin resistance in skeletal muscle: impaired GLUT4 translocation is followed by a reduced GLUT4 intrinsic activity. *Am J Physiol Endocrinol Metab.* **293** (3), E783-793 (2007).
29. Coll, T. *et al.* Oleate reverses palmitate-induced insulin resistance and inflammation in skeletal muscle cells. *J Biol Chem.* **283** (17), 11107-11116 (2008).
30. Gaster, M., Rustan, A. C., & Beck-Nielsen, H. Differential utilization of saturated palmitate and unsaturated oleate: evidence from cultured myotubes. *Diabetes.* **54** (3), 648-656, (2005).

31. Hage Hassan, R. *et al.* Endoplasmic reticulum stress does not mediate palmitate-induced insulin resistance in mouse and human muscle cells. *Diabetologia*. **55** (1), 204-214 (2012).
32. Haghani, K., Pashaei, S., Vakili, S., Taheripak, G., & Bakhtiyari, S. TNF-alpha knockdown alleviates palmitate-induced insulin resistance in C2C12 skeletal muscle cells. *Biochem Biophys Res Commun*. **460** (4), 977-982 (2015).
33. Hommelberg, P. P. *et al.* Palmitate-induced skeletal muscle insulin resistance does not require NF-kappaB activation. *Cell Mol Life Sci*. **68** (7), 1215-1225 (2011).
34. Yang, M. *et al.* Saturated fatty acid palmitate-induced insulin resistance is accompanied with myotube loss and the impaired expression of health benefit myokine genes in C2C12 myotubes. *Lipids Health Dis*. **12** 104 (2013).
35. Peng, G. *et al.* Oleate blocks palmitate-induced abnormal lipid distribution, endoplasmic reticulum expansion and stress, and insulin resistance in skeletal muscle. *Endocrinology*. **152** (6), 2206-2218 (2011).
36. Lambernd, S. *et al.* Contractile activity of human skeletal muscle cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. *Diabetologia*. **55** (4), 1128-1139 (2012).
37. Nikolic, N. *et al.* Electrical pulse stimulation of cultured human skeletal muscle cells as an in vitro model of exercise. *PLoS One*. **7** (3), e33203 (2012).
38. Hsu, F. L. *et al.* Antidiabetic effects of pteroin A, a small-molecular-weight natural product, on diabetic mouse models. *Diabetes*. **62** (2), 628-638 (2013).
39. Zou, C., Wang, Y., & Shen, Z. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. *J Biochem Biophys Methods*. **64** (3), 207-215 (2005).
40. Catalano, K. J. *et al.* Insulin resistance induced by hyperinsulinemia coincides with a persistent alteration at the insulin receptor tyrosine kinase domain. *PLoS One*. **9** (9), e108693 (2014).
41. Liu, H. Y. *et al.* Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). *J Biol Chem*. **284** (40), 27090-27100 (2009).
42. Renstrom, F., Buren, J., Svensson, M., & Eriksson, J. W. Insulin resistance induced by high glucose and high insulin precedes insulin receptor substrate 1 protein depletion in human adipocytes. *Metabolism*. **56** (2), 190-198 (2007).